The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1270 articles
A large study presented in San Diego reveals semaglutide use is not associated with higher risk of non-arteritic anterior ischemic optic neuropathy (NAION) in patients with overweight or obesity. In fact, it lowered NAION risk by 64% among those with type 2 diabetes compared to non-GLP-1 therapies. Experts emphasize continued monitoring of blood sugar and blood pressure.
Jelon Smart from Savannah dropped 110 pounds on Ozempic—but credits her intensive workout regimen too. Facing severe ankle swelling from Achilles tendinitis at 285 pounds, she transformed her life. Doctors remind GLP-1 users: movement and mental health are essential alongside medication.
It starts with an Instagram reel from an influencer hyping potent weight-loss peptides. Soon, Indians dive into YouTube explainers, Reddit threads, and chat groups, ending with unapproved shipments from China. Hundreds rely on these cheaper alternatives to pricey Mounjaro and Ozempic amid GLP-1 plateaus.
Counterfeit versions of retatrutide, a promising but unapproved weight loss drug, are flooding online markets despite ongoing phase 3 clinical trials. Experts like obesity specialist Samantha Hocking highlight its potential for 29% body weight loss by targeting GLP-1, GIP, and glucagon. However, doctors and Eli Lilly warn of serious risks from these fake products.
More Americans are prioritizing meat for protein, with 75% seeing it as healthy—up from 64% in 2020. But experts like Tufts' Erin Hennessy caution against overfixating on meat amid industry pushes and RFK Jr.'s endorsements. Discover the health risks and smarter protein alternatives.
Eli Lilly's Foundayo, a groundbreaking once-daily oral GLP-1 pill for weight loss, is now shipping nationwide in the US following FDA approval. Backed by the ATTAIN trials, it delivered an average 27-pound loss at the highest dose. Discover access options, pricing, and what patients need to know.
New research from 23andMe reveals genetic variants in GLP1R that boost weight loss from GLP-1 drugs by up to 3.3 pounds. GIPR mutations increase vomiting risk on tirzepatide. Meanwhile, semaglutide's heart benefits appear independent of weight loss, opening doors to precision dosing.
GLP-1 medications like Ozempic are transforming lives but also sparking a spending frenzy far beyond drug costs. From gym memberships to combat muscle loss to entire wardrobe replacements, users like sales executive Kelly Freeman are spending $700-$1,000 monthly. Industries from fitness to plastic surgery are reaping windfalls.
Amazon is revolutionizing access to GLP-1 weight-loss drugs by launching same-day delivery for Foundayo through Amazon Pharmacy in nearly 3,000 cities. Patients can now order with a valid prescription, check real-time availability, and get medication home-delivered faster than traditional options. This move cuts treatment barriers from prescription to doorstep.
